Patent · US Active

Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies

US9068230B2 · kind B2 · utility

0Cited by
27References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 7, 2008
Grant dateJun 30, 2015
Priority date—
Expiry dateNov 7, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/158
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.